Cited by 10Organ Transplantation Techniques and OutcomesLiver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Clinical evidence of outcomes following liver transplantation in patients with nonalcoholic steatohepatitis: an updated meta-analysis and systematic review

Open access
Zhou, Guang-Peng, Jiang, Yi-Zhou, Sun, Li-Ying, Zhu, Zhi-Jun·2022·International Journal of Surgery

Abstract

OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is a dramatically growing indication for liver transplantation (LT) worldwide and the posttransplant outcomes of NASH patients are currently under intensive investigation. This quantitative meta-analysis aimed to update the clinical evidence on outcomes of transplanted patients with NASH. METHODS: We performed a systematic review and meta-analysis of studies (published up to September 15, 2021) that focused on LT outcomes for NASH versus non-NASH patients. Random-effect meta-analysis was conducted to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup analyses based on crucial baseline clinical characteristics and leave-one-out sensitivity analyses were conducted to assess the robustness of the pooled results. Meta-regression was used to evaluate study-level demographic, clinical, and biochemical characteristics to identify potential confounders affecting patient survival. RESULTS: Twenty-two non-randomized comparative studies with 1,538 NASH and 6,014 non-NASH patients were included. 1- (OR, 0.94; 95% CI, 0.77-1.14), 3- (OR, 0.82; 95% CI, 1.00-1.22), and 5- (OR, 1.05; 95% CI, 0.84-1.31) year patient survival was equivalent between NASH and non-NASH recipients. NASH patients were associated with similar cardiovascular mortality (OR, 1.36; 95% CI, 0.89-2.09) and retransplantation rates (OR, 0.69; 95% CI, 1.03-1.53), lower graft failure-related mortality (OR, 0.11; 95% CI, 0.29-0.74), but higher sepsis-related mortality (OR, 1.53; 95% CI, 1.13-2.06). Meta-regression revealed that a higher proportion of patients with hepatocellular carcinoma (HCC) were associated with significantly superior overall patient survival at 1 (P = 0.044), 3 (P = 0.035) and 5 (P = 0.049) years after LT in NASH compared with non-NASH. CONCLUSIONS: This study shows no difference in posttransplant survival between NASH and non-NASH patients. Carefully selected patients with NASH-related HCC may benefit from LT. NASH recipients should be managed with caution posttransplant, especially regarding the potentially high risk of sepsis-related death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijsu.2022.106752

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Long-term graft and recipient survival after liver transplantation do not differ in many retrospective and registry analyses between adults with MASLD and others.

    “Despite the overall higher rate of risk factors in adults with MASLD, long-term graft and recipient survival after liver transplantation do not differ in many retrospective and registry analyses, 482,486,487 supporting that candidates with MASLD can be safely transplanted, if properly”

    From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [487]

    Sections 3.2.2–3.2.3 report similar 3- and 5-year patient survival after transplantation for NASH and non-NASH recipients. The paper does not establish equivalent long-term graft survival: Section 3.3.3 instead reports lower graft failure-related mortality in the NASH group. Its comparison concerns NASH, which is narrower than MASLD. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 41 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. F. Ferla, I. Vella, A. Ficarelli, R. De Carlis, A. Lauterio, et al., Does NASH jeopardize liver transplant survival IN HCC patients? The niguarda experience, Transpl. Int. 34 (2021), 336-336.
  2. N.A. Piazza, A.K. Singal, Frequency of cardiovascular events and effect on survival in liver transplant recipients for cirrhosis due to alcoholic or nonalcoholic steatohepatitis, Exp Clin Transplant 14 (2016) 79-85, https://doi.org/10.6002/ ect.2015.0089. · DOI

Cited by

Sorted by citations

Authors
Zhou, G.-P., Jiang, Y.-Z., Sun, L.-Y., & Zhu, Z.-J.
Affiliations
Capital Medical University (CN)
Corresponding author
  • Sun, Li-Ying
  • Zhu, Zhi-Jun
Venue
International Journal of Surgery
Published
2022-08
Volume
104
Pages
106752
ISSN
  • 1743-9159 (ISSN-L)
  • 1743-9191
OpenAlex
W4284699430
Cited by
10
References
41
Citations by year
2025: 3 · 2024: 3 · 2023: 2 · 2022: 2
FWCI
0.59
Type
journal article
Language
en
Open access
Locations
  • International Journal of Surgery (publishedVersion)
  • PubMed (publishedVersion)
Funders
Beijing Postdoctoral Science Foundation
Topics
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
nonalcoholic steatohepatitis, liver transplantation, post-transplant outcomes, patient survival, graft failure, sepsis mortality, cardiovascular mortality, retransplantation, hepatocellular carcinoma, liver disease severity, post-transplant complications, liver fibrosis
MeSH terms
Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Retrospective Studies, Liver Transplantation, Treatment Outcome, Sepsis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review